Fragmentation Pattern of Cell-Free DNA Can Reveal Cancer, Even at Early Stages
Machine learning algorithm detected 7 types of cancer in liquid biopsy and identified tissue of disease origin.
Chronic Myeloid Leukemia
CHRONIC MYELOID LEUKEMIA ADVISOR
FEATURED CONTENT
-
-
Solving the Obesity Paradox in Oncology
One potentially revolutionary hypothesis relates to the evolutionary processes involved in oncogenesis. -
Multidisciplinary Genetic Tumor Boards: Critical for Interpreting Tumor-Only Sequencing Results
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results. -
In-House or Centralized Testing? Debating Whether Genomic Sequencing Is Best Conducted at Home
Genomic analysis of tumors and tests measuring certain biomarkers can be done in-house or sent out. What are the costs and benefits of each approach? -
What Do Surrogate End Points Actually Predict?
As understanding of cancer improves, drug development could become accelerated, necessitating a means for determining whether a drug is actually effective.
VIDEO SERIES
Ponatinib for CML
Progress in the CML Landscape
Treatment Options
Sequencing Treatment
Choosing the Appropriate TKI
Monitoring Treatment Response
Monitoring Adherence
Switching Therapies
Discontinuing Treatment
Known Factors in TKI Resistance
Managing Adverse Events
Allogeneic Stem Cell Transplant
CML: On the Horizon
The Future of CML Treatment
CHRONIC MYELOID LEUKEMIA NEWS
Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid Leukemia
Second-Generation TKIs in Advanced CML: 7-Year Survival Rates
Generic Imatinib Compared With Gleevec in CP-CML: Patient Outcomes Across 3 Countries
Prototype Intervention Increased Adherence to TKIs in CML
Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
Want to read more?
Please login or register first to view this content.
Next post in Chronic Myeloid Leukemia
